WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million
WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global uncertainties.
WuXi Biologics: Spotlight On Property Disposal And Operating Metrics (Rating Upgrade)
WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...
Wuxi Biologics Sells Vaccines Ireland Facility for $500M
Wuxi Biologics (Cayman) ( (HK:2269) ) has provided an announcement.
WuXi Biologics: Buy Rating Supported by Strong Performance, Strategic Growth, and Increased Target Price
CMB International Securities analyst Jill Wu has maintained their bullish stance on WXIBF stock, giving a Buy rating on January 13.Stay Ahead ...
China's WuXi Biologics to sell Irish vaccine facility to Merck for $500 million
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about $500 million. The Financial Times had reported in October that WuXi and WuXi ...